Johnson & Johnson Stock price

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2023-12-05 pm EST Intraday chart for Johnson & Johnson 5-day change 1st Jan Change
158.55 USD -0.21% +4.56% -10.25%
Sales 2023 * 85.4B Sales 2024 * 88.51B Capitalization 382B
Net income 2023 * 18.65B Net income 2024 * 22.37B EV / Sales 2023 *
4,56x
Net Debt 2023 * 8.08B Net cash position 2024 * 2.87B EV / Sales 2024 *
4,28x
P/E ratio 2023 *
21,3x
P/E ratio 2024 *
18,0x
Employees 152,700
Yield 2023 *
2,95%
Yield 2024 *
3,07%
Free-Float 77.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.37%
1 week+4.56%
Current month+2.52%
1 month+4.76%
3 months-1.33%
6 months+0.15%
Current year-10.25%
More quotes
1 week
151.92
Extreme 151.92
160.02
1 month
145.64
Extreme 145.64
160.02
Current year
144.95
Extreme 144.95
180.93
1 year
144.95
Extreme 144.95
181.04
3 years
144.95
Extreme 144.95
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 1988
Director of Finance/CFO - 2009
Director of Finance/CFO 56 1997
Members of the board TitleAgeSince
Director/Board Member 70 2019
Director/Board Member 71 2014
Director/Board Member 70 2009
More insiders
Date Price Change Volume
23-12-05 158.55 -0.21% 7,268,151
23-12-04 158.88 +0.32% 8,920,279
23-12-01 158.38 +2.41% 10,342,901
23-11-30 154.66 +1.68% 12,481,867
23-11-29 152.11 +0.32% 5,190,026

Delayed Quote Nyse, December 05, 2023 at 04:00 pm EST

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
158.55USD
Average target price
174.55USD
Spread / Average Target
+10.09%
Consensus
1st Jan change Capi.
-10.25% 382 B $
+60.77% 529 B $
+46.50% 444 B $
-4.25% 269 B $
-10.54% 255 B $
-13.61% 231 B $
+1.76% 200 B $
-9.57% 198 B $
-43.23% 164 B $
+3.13% 145 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Johnson & Johnson - Nyse
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer